Alprazolam Tab — Class II drug recall D-0504-2023
Terminated recall by Preferred Pharmaceuticals, Inc., reported 2023-04-12, distributed nationwide. CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Conta
| Recall number | D-0504-2023 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Preferred Pharmaceuticals, Inc., Anaheim, CA, United States |
| Recall initiated | 2023-03-27 |
| Classified | 2023-04-05 |
| Reported by FDA | 2023-04-12 |
| Terminated | 2023-10-24 |
| Distributed | Nationwide (US) |
| Quantity | 30 bottles |
| Reason classes | cgmp |
| NDC | 68788-7594-03 |
| Lot numbers | G1822K |
| Expiration dates | 2023-05-31 |
Product
Alprazolam Tab, USP 0.25mg, (CIV), 30-count bottle, Rx Only, Preferred Pharmaceuticals, Inc. Manufactured by: Breckenridge Pharmaceuticals, Inc., Boca Raton, FL. Ins:NDC 68788-7594-3
Reason for recall
CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0504-2023. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.